JP2013510870A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510870A5
JP2013510870A5 JP2012538997A JP2012538997A JP2013510870A5 JP 2013510870 A5 JP2013510870 A5 JP 2013510870A5 JP 2012538997 A JP2012538997 A JP 2012538997A JP 2012538997 A JP2012538997 A JP 2012538997A JP 2013510870 A5 JP2013510870 A5 JP 2013510870A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012538997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510870A (ja
JP5723381B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056449 external-priority patent/WO2011060217A1/en
Publication of JP2013510870A publication Critical patent/JP2013510870A/ja
Publication of JP2013510870A5 publication Critical patent/JP2013510870A5/ja
Application granted granted Critical
Publication of JP5723381B2 publication Critical patent/JP5723381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012538997A 2009-11-16 2010-11-12 Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 Active JP5723381B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382245.0 2009-11-16
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
US61/298,628 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013510870A JP2013510870A (ja) 2013-03-28
JP2013510870A5 true JP2013510870A5 (enExample) 2013-11-21
JP5723381B2 JP5723381B2 (ja) 2015-05-27

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012538997A Active JP5723381B2 (ja) 2009-11-16 2010-11-12 Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物

Country Status (18)

Country Link
US (1) US20120214784A1 (enExample)
EP (1) EP2501704B1 (enExample)
JP (1) JP5723381B2 (enExample)
KR (1) KR101368130B1 (enExample)
CN (1) CN102666550B (enExample)
AU (1) AU2010319400B2 (enExample)
BR (1) BR112012011710A2 (enExample)
CA (1) CA2781041C (enExample)
DK (1) DK2501704T3 (enExample)
EA (1) EA020391B1 (enExample)
ES (1) ES2436241T3 (enExample)
HR (1) HRP20130969T1 (enExample)
MX (1) MX2012005690A (enExample)
PL (1) PL2501704T3 (enExample)
PT (1) PT2501704E (enExample)
RS (1) RS53017B (enExample)
SI (1) SI2501704T1 (enExample)
WO (1) WO2011060217A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388468B (es) 2009-12-04 2025-03-20 Sunovion Pharmaceuticals Inc Compuestos multicíclicos y métodos de uso de los mismos.
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
AR105821A1 (es) * 2015-09-09 2017-11-15 Lilly Co Eli COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
RU2019106494A (ru) 2016-08-10 2020-09-14 Байер Кропсайенс Акциенгезельшафт Замещенные 2-гетероциклил-имидазолил-карбоксамиды в качестве средств для борьбы с вредителями
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sumitomo Pharma America, Inc. Methods of treating schizophrenia
WO2018160547A1 (en) * 2017-03-02 2018-09-07 Eli Lilly And Company Compounds useful for inhibiting ror-gamma-t
SI3589638T1 (sl) 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
MY208150A (en) 2018-02-16 2025-04-18 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
JP7781768B2 (ja) 2020-04-14 2025-12-08 スミトモ・ファーマ・アメリカ・インコーポレイテッド 神経学的および精神障害の治療方法
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0509377A (pt) * 2004-03-29 2007-09-11 Pfizer compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1890696A4 (en) * 2005-06-02 2010-05-05 Janssen Pharmaceutica Nv Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives

Similar Documents

Publication Publication Date Title
JP2013510870A5 (enExample)
JP2013510859A5 (enExample)
HRP20130969T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
JP6572294B2 (ja) 殺菌・殺カビ性アゾ環式アミド
CA2699933C (en) Fungicidal mixtures
DK2576543T3 (en) Pyrazole compounds as sigma receptor inhibitors
ES2568882T3 (es) Derivado de azol
HRP20130967T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
ME01462B (me) Vinilindazolilna jedinjenja"
JP2013517281A5 (enExample)
JP2016535772A5 (enExample)
WO2013042138A3 (en) Process for preparation of triazole antifungal drug, its intermediates and polymorphs thereof
JP2015193641A (ja) JANUSキナーゼ阻害剤としてのヘテロアリール置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−b]ピリミジン
JP2016519156A5 (enExample)
JP2017039755A5 (enExample)
RU2016102647A (ru) Ингибиторы бромодомена
JP2013532709A5 (enExample)
BRPI0807014A2 (pt) Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
JP2008513500A5 (enExample)
AR072201A1 (es) 2-arilaminoquinazolinas para el tratamiento de enfermedades proliferativas
JP2014501732A5 (enExample)
MX2013002400A (es) Pirazoles fungicidas.
RU2017107506A (ru) Конденсированные 11-членные соединения и содержащие их сельскохозяйственные/садоводческие фунгициды
RU2015148766A (ru) Комбинации лигандов альфа-2 адренорецептора и сигма рецептора
RU2019123319A (ru) Пиразолопиримидины и способы их применения